Great Lakes Advisors LLC Purchases New Position in United Therapeutics Corporation $UTHR

Great Lakes Advisors LLC bought a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 7,399 shares of the biotechnology company’s stock, valued at approximately $4,009,000.

Several other hedge funds have also recently modified their holdings of the business. Torren Management LLC bought a new stake in United Therapeutics in the 4th quarter worth about $26,000. Activest Wealth Management grew its stake in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the period. WealthCollab LLC raised its holdings in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. lifted its position in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the period. Finally, Entrust Financial LLC purchased a new stake in United Therapeutics in the fourth quarter worth approximately $31,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $521.00 on Friday. United Therapeutics Corporation has a one year low of $302.19 and a one year high of $609.35. The business has a fifty day moving average price of $533.74 and a 200-day moving average price of $537.53. The firm has a market capitalization of $22.35 billion, a price-to-earnings ratio of 18.64, a price-to-earnings-growth ratio of 1.79 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same period in the previous year, the business earned $6.41 earnings per share. United Therapeutics’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, equities research analysts expect that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $547.62, for a total value of $5,202,390.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,185,729.06. This represents a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the sale, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,311,581.28. The trade was a 34.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 434,275 shares of company stock worth $234,984,268 in the last ninety days. Corporate insiders own 8.60% of the company’s stock.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several research analyst reports. Royal Bank Of Canada lowered their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $575.00 to $735.00 in a report on Thursday, May 7th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. Finally, JPMorgan Chase & Co. upped their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $646.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.